---
title: "Vraylar (cariprazine), all indications: Pharmacology questions"
description: "Pharmacology questions on Vraylar (cariprazine) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Vraylar work (mechanism of action)? Which receptors does Vraylar bind to? How is Vraylar metabolized? Is Vraylar excreted by the kidneys? 3 further questions follow. 7 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine), all indications: Pharmacology questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)

## Mechanism

<a id="vraylar-mechanism"></a>

### How does Vraylar work (mechanism of action)?

> “The mechanism of action of VRAYLAR is unknown. The efficacy of VRAYLAR is thought to be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Mechanism of Action, captured 2026-11-13](https://www.vraylarhcp.com/pharmacology/mechanism-of-action#:~:text=The%20mechanism%20of%20action%20of,antagonist%20activity%20at%20serotonin%205%2DHT2A)

> “May act as an agonist to increase signaling when neurotransmitters are low<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Mechanism of Action, captured 2026-11-13](https://www.vraylarhcp.com/pharmacology/mechanism-of-action#:~:text=May%20act%20as%20an%20agonist%20to%20increase%20signaling%20when%20neurotransmitters%20are)

> “May act as an antagonist to decrease signaling when neurotransmitters are high<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Mechanism of Action, captured 2026-11-13](https://www.vraylarhcp.com/pharmacology/mechanism-of-action#:~:text=May%20act%20as%20an%20antagonist%20to%20decrease%20signaling%20when%20neurotransmitters%20are)

<a id="vraylar-receptor-binding"></a>

### Which receptors does Vraylar bind to?

> “Cariprazine acts as a partial agonist at the dopamine D3 and D2 receptors with high binding affinity (Ki 
> values 0.085 nM, and 0.49 nM (D2L) and 0.69 nM (D2S), respectively) and at the serotonin 5-HT1A 
> receptors (Ki value 2.6 nM). Cariprazine acts as an antagonist at 5-HT2B and 5-HT2A receptors with high 
> and moderate binding affinity (Ki values 0.58 nM and 18.8 nM respectively) as well as it binds to the 
> histamine H1 receptors (Ki value 23.2 nM). Cariprazine shows lower binding affinity to the serotonin 5-
> HT2C and α1A- adrenergic receptors (Ki values 134 nM and 155 nM, respectively) and has no appreciable 
> affinity for cholinergic muscarinic receptors (IC50>1000 nM).”

Source: [VRAYLAR: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=31)

> “VRAYLAR demonstrated up to ~8-fold greater in vitro affinity for dopamine D3 vs D2 receptors<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Mechanism of Action, captured 2026-11-13](https://www.vraylarhcp.com/pharmacology/mechanism-of-action#:~:text=VRAYLAR%20demonstrated%20up%20to%20~8%2Dfold,for%20dopamine%20D3%20vs%20D2)

> “The clinical significance of the in vitro data is unknown.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Mechanism of Action, captured 2026-11-13](https://www.vraylarhcp.com/pharmacology/mechanism-of-action#:~:text=The%20clinical%20significance%20of%20the%20in%20vitro%20data%20is%20unknown.)

## Pharmacokinetics

<a id="vraylar-metabolism"></a>

### How is Vraylar metabolized?

> “Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6 to DCAR and 
> DDCAR. DCAR is further metabolized into DDCAR by CYP3A4 and CYP2D6. DDCAR is then 
> metabolized by CYP3A4 to a hydroxylated metabolite.”

Source: [VRAYLAR: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=32)

> “VRAYLAR activity is thought to be mediated by cariprazine and its two major active metabolites, 
> desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), which are pharmacologically 
> equipotent to cariprazine.”

Source: [VRAYLAR: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=31)

<a id="vraylar-excretion"></a>

### Is Vraylar excreted by the kidneys?

> “Following administration of 12.5 mg/day cariprazine to patients with schizophrenia for 27 days, about 
> 21% of the daily dose was found in urine, with approximately 1.2% of the daily dose excreted in urine as 
> unchanged cariprazine.”

Source: [VRAYLAR: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=33)

> “Cariprazine and its major active metabolites are minimally excreted in urine. Pharmacokinetic analyses 
> indicated no significant relationship between plasma clearance and creatinine clearance”

Source: [VRAYLAR: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=33)

<a id="vraylar-half-life"></a>

### How long does Vraylar stay in your system (half-life)?

> “~7-day half-life<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=~7%2Dday)

> “VRAYLAR plasma concentration decreased by ~50% in approximately 1 week<sup>‡</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=VRAYLAR%20plasma%20concentration%20decreased%20by%20~50%25%20in%20approximately%201)

> “‡After multiple dose administration of VRAYLAR, mean cariprazine and DCAR concentrations reached steady state at around Week 1 to Week 2 and mean DDCAR concentrations approached steady state around Week 4 to Week 8 in a 12-week study. The half-lives based on time to reach steady state were 2 to 4 days for cariprazine, ~1 to 2 days for DCAR, and approximately 1 to 3 weeks for DDCAR. The time to reach steady state for DDCAR was variable across patients, with some not achieving steady state at the end of the 12-week treatment. After discontinuation of VRAYLAR, mean plasma concentrations of cariprazine and DCAR decreased by ~50% in ~1 day, and mean plasma concentration of DDCAR decreased by ~50% 1 week after the last dose. The decline in plasma concentrations of active drug and metabolites may not be immediately reflected in patients’ clinical symptoms.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=%E2%80%A1After%20multiple%20dose%20administration%20of,immediately%20reflected%20in%20patients%E2%80%99%20clinical)

> “There was an approximately 90% decline in plasma exposure within 1 week for cariprazine and DCAR, 
> and at about 4 weeks for DDCAR. Following a single dose of 1 mg of cariprazine administration, 
> DDCAR remained detectable 8 weeks post-dose.”

Source: [VRAYLAR: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=32)

<a id="vraylar-peak-concentration"></a>

### How fast does Vraylar reach peak levels?

> “~3-6 hours to peak plasma concentration<sup>1</sup>
>
> after 1 dose of VRAYLAR 1.5 mg/day”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=~3%2D6%20hours%20to%20peak%20plasma,dose%20of%20VRAYLAR%201.5%20mg%2Fday)

> “After single dose administration of VRAYLAR, the peak plasma cariprazine concentration occurred in 
> approximately 3-6 hours.”

Source: [VRAYLAR: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=32)

## Components

<a id="vraylar-inactive-ingredients"></a>

### What are the inactive ingredients in Vraylar?

> “VRAYLAR capsules are intended for oral administration only. Each hard gelatin capsule contains 0.5, 
> 0.75, 1.5, 3, 4.5, or 6 mg of cariprazine base (equivalent to 0.545 mg, 0.818 mg, 1.635 mg , 3.27 mg, 
> 4.905 mg, or 6.54 mg cariprazine HCl). In addition, capsules include the following inactive ingredients: 
> gelatin, magnesium stearate, pregelatinized starch, shellac, and titanium dioxide. Colorants include black 
> iron oxide (0.5, 0.75, 1.5, 3, and 6 mg), FD&C Blue 1 (0.5, 0.75, 3, 4.5, and 6 mg), FD&C Red 3 (6 mg), 
> FD&C Red 40 (3 and 4.5 mg), or yellow iron oxide (0.5, 3, and 4.5 mg).”

Source: [VRAYLAR: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=31)

## Related pages
- [Medical information: Vraylar (cariprazine): All indications](https://www.evicenter.com/medical-information/vraylar)
- [Indication](https://www.evicenter.com/medical-information/vraylar/indication)
- [Safety](https://www.evicenter.com/medical-information/vraylar/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vraylar/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vraylar/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vraylar/storage-and-supply)
